Tyagarajan N. V. 4

4 · Genpact LTD · Filed May 22, 2023

Form 4

Period: 2023-05-18

Chief Operating Officer

Transactions

Exercise/Conversion
Common Shares
2023-05-18$19.35/sh+50,000$967,500→ 855,509 total
Sale
Common Shares
2023-05-19$38.49/sh−50,000$1,924,305→ 805,509 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-05-18−50,000→ 50,000 total
Exercise: $19.35Exp: 2023-05-30→ Common Shares (50,000 underlying)
Sale
Common Shares
2023-05-18$37.95/sh−50,000$1,897,300→ 805,509 total
Exercise/Conversion
Common Shares
2023-05-19$19.35/sh+50,000$967,500→ 855,509 total
Exercise/Conversion
Employee Stock Option (Right to Buy)
2023-05-19−50,000→ 0 total
Exercise: $19.35Exp: 2023-05-30→ Common Shares (50,000 underlying)

Holdings

Footnotes (5)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2022.
[F2]The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $37.69 to $38.222. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]The price in Column 4 is a weighted average price. The actual sales prices for these transactions ranged from $38.07 to $38.98. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]These shares are held in trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is one of the trustees of the trust. The reporting person disclaims beneficial ownership of the reported securities held by the trust except to the extent of his pecuniary interest therein.
[F5]The option vested 50% on January 10, 2016 and the remainder on January 10, 2018.

Documents

1 file